Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (IRIS)

First posted November 30, 2021, Updated May 20, 2022; Recruiting

This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class V).

To Learn More Contact

Contact: AstraZeneca Clinical Study Information at 1-877-240-9479 or information.center@astrazeneca.com

ClinicalTrials.gov identifier (NCT number): NCT05138133

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up